atenolol has been researched along with Atrial Fibrillation in 66 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 9.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| " We examined whether PP predicted new-onset AF in comparison with other blood pressure components in the Losartan Intervention For Endpoint reduction in hypertension study, a double-blind, randomized (losartan versus atenolol), parallel-group study, including 9193 patients with hypertension and electrocardiographic left ventricular hypertrophy." | 9.16 | Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| "To compare the effects of nebivolol, a new b-blocker that have additional vasodilating activity via acting on endothelium and nitric oxide release, and atenolol on P-wave duration and dispersion in patients with mild-to-moderate hypertension." | 9.13 | [Comparison of effects of nebivolol and atenolol on P-wave dispersion in patients with hypertension]. ( Batyraliev, TA; Eryonucu, B; Fettser, DV; Guler, N; Gumrukchuoglu, KhA; Gunes, Y; Guntekin, U; Sidorenko, BA; Tuncer, M, 2008) |
| "The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation." | 9.13 | Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "Evaluate the effects of optimized atrial stimulation--OAS (dual-site atrial pacing, heart rate above the intrinsic rate, and specific functional algorithm), and the use of atenolol in preventing recurrent atrial fibrillation (AF)." | 9.12 | Effects of the association of dual-site dynamic atrial overdrive and atenolol in preventing recurrent atrial fibrillation. ( Costa, R; Martinelli Filho, M; Menezes, Ada S; Menezes, CC; Ramires, JA, 2007) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy." | 9.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "Oral low-dose sotalol provides a considerable reduction in the occurrence of atrial fibrillation." | 9.11 | Preoperative use of sotalol versus atenolol for atrial fibrillation after cardiac surgery. ( Blasco, M; Carbonell, N; Jordá, A; Martínez-León, J; Núñez, J; Otero, E; Sanjuán, R, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 9.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up." | 9.11 | Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005) |
| "No difference was found in terms of ECG or symptomatic control of paroxysmal atrial fibrillation between prescribing sotalol 80 mg twice daily and atenolol 50 mg once daily." | 9.09 | An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. ( Birchall, AS; Channer, KS; Smith, M; Steeds, RP, 1999) |
| " The purpose of this article is to review post hoc sub-analyses of LIFE study data and other clinical studies that offer some insight into possible treatment-related differences contributing to the superior stroke outcome of losartan versus atenolol beyond blood pressure reduction." | 8.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| " This case-based review describes the risk and benefits of prescribing antithrombotic therapy for a hypothetical 80-year-old man who has atrial fibrillation and hypertension, and it offers practical advice on managing warfarin therapy." | 8.81 | Warfarin therapy for an octogenarian who has atrial fibrillation. ( Fihn, SD; Gage, BF; White, RH, 2001) |
| "The benefits of digoxin in patients with atrial fibrillation may be reduced due to its limited effect on atrioventricular conduction." | 7.69 | [Comparison between digoxin and atenolol in chronic atrial fibrillation]. ( Castillo, G; Lanas, F; Molina, E; Montecinos, A; Salvatici, R; Stockins, B, 1995) |
| "Treatment with atenolol was associated with a marked reduction in maximum treadmill walking distance (mean 356 m) as compared both with placebo (mean 421 m, p less than 0." | 6.66 | Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. ( Lewis, RV; McDevitt, DG; McMurray, J, 1989) |
| " The risk of new-onset AF was examined in relation to last in-treatment SBP before AF diagnosis or last in-study measurement in the absence of new AF in 8831 hypertensive patients with ECG left ventricular hypertrophy with no history of AF, in sinus rhythm on their baseline ECG, randomly assigned to losartan- or atenolol-based treatment." | 5.20 | Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Larstorp, AC; Okin, PM; Wachtell, K, 2015) |
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 5.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| "In the Losartan Intervention For Endpoint reduction in Hypertension (LIFE) study, a double-blinded, randomized, parallel-group study, 9193 hypertensive patients with electrocardiogram (ECG)-documented left ventricular hypertrophy (LVH), randomized to once-daily losartan- or atenolol-based antihypertensive therapy were followed for a mean of 4." | 5.16 | Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Okin, PM; Olsen, MH; Reims, HM; Wachtell, K, 2012) |
| " We examined whether PP predicted new-onset AF in comparison with other blood pressure components in the Losartan Intervention For Endpoint reduction in hypertension study, a double-blind, randomized (losartan versus atenolol), parallel-group study, including 9193 patients with hypertension and electrocardiographic left ventricular hypertrophy." | 5.16 | Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| " Although losartan therapy and decreasing ECG left ventricular hypertrophy are associated with decreased AF incidence, the relationship of HR changes over time to development of AF has not been examined." | 5.13 | Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K, 2008) |
| "The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation." | 5.13 | Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "To compare the effects of nebivolol, a new b-blocker that have additional vasodilating activity via acting on endothelium and nitric oxide release, and atenolol on P-wave duration and dispersion in patients with mild-to-moderate hypertension." | 5.13 | [Comparison of effects of nebivolol and atenolol on P-wave dispersion in patients with hypertension]. ( Batyraliev, TA; Eryonucu, B; Fettser, DV; Guler, N; Gumrukchuoglu, KhA; Gunes, Y; Guntekin, U; Sidorenko, BA; Tuncer, M, 2008) |
| "Double-blind, randomized, parallel-group study conducted in 1995-2001 among 8831 men and women with hypertension, aged 55-80 years (median, 67 years), with electrocardiographic LVH by Cornell voltage-duration product or Sokolow-Lyon voltage, with no history of AF, without AF on the baseline electrocardiogram, and enrolled in the Losartan Intervention for Endpoint Reduction in Hypertension Study." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. ( Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Hille, DA; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K, 2006) |
| "Evaluate the effects of optimized atrial stimulation--OAS (dual-site atrial pacing, heart rate above the intrinsic rate, and specific functional algorithm), and the use of atenolol in preventing recurrent atrial fibrillation (AF)." | 5.12 | Effects of the association of dual-site dynamic atrial overdrive and atenolol in preventing recurrent atrial fibrillation. ( Costa, R; Martinelli Filho, M; Menezes, Ada S; Menezes, CC; Ramires, JA, 2007) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy." | 5.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up." | 5.11 | Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 5.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "Oral low-dose sotalol provides a considerable reduction in the occurrence of atrial fibrillation." | 5.11 | Preoperative use of sotalol versus atenolol for atrial fibrillation after cardiac surgery. ( Blasco, M; Carbonell, N; Jordá, A; Martínez-León, J; Núñez, J; Otero, E; Sanjuán, R, 2004) |
| "This study indicates that digoxin and diltiazem, as single agents at the doses tested, are least effective for controlling ventricular rate in atrial fibrillation during daily activity." | 5.09 | Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. ( Farshi, R; Kistner, D; Longmate, JA; Sarma, JS; Singh, BN, 1999) |
| "No difference was found in terms of ECG or symptomatic control of paroxysmal atrial fibrillation between prescribing sotalol 80 mg twice daily and atenolol 50 mg once daily." | 5.09 | An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. ( Birchall, AS; Channer, KS; Smith, M; Steeds, RP, 1999) |
| "Baseline tachycardia or symptoms suggesting anxiety, emotional tension or sympathetic overactivity are associated with a more pronounced blood pressure fall to antihypertensive treatment with atenolol." | 5.09 | [Relationship between sympathetic activity and response to treatment with atenolol in hypertensive patients. Investigation group of the study of efficiency and tolerance of atenolol in hypertensive patients with increase in the sympathetic activity]. ( de la Sierra, A, 1999) |
| " β blockers, alone or in combination with digoxin, or non-dihydropyridine calcium-channel blockers (not in heart failure) effectively lower the heart rate." | 4.93 | Rate control in atrial fibrillation. ( Crijns, HJ; Olshansky, B; Rienstra, M; Van Gelder, IC, 2016) |
| "An 88-year-old female, living independently in the community, developed duodenal and gastric ulcers from using overthe-counter naproxen sodium for pain related to a shoulder fracture and arthritis of the knees." | 4.88 | Gastrointestinal bleeding and possible hypothyroidism. ( Marshall, LL, 2012) |
| " The purpose of this article is to review post hoc sub-analyses of LIFE study data and other clinical studies that offer some insight into possible treatment-related differences contributing to the superior stroke outcome of losartan versus atenolol beyond blood pressure reduction." | 4.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| "The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy." | 4.82 | Implications of the LIFE trial. ( Lim, HS; Lip, GY; Nadar, S, 2003) |
| " This case-based review describes the risk and benefits of prescribing antithrombotic therapy for a hypothetical 80-year-old man who has atrial fibrillation and hypertension, and it offers practical advice on managing warfarin therapy." | 4.81 | Warfarin therapy for an octogenarian who has atrial fibrillation. ( Fihn, SD; Gage, BF; White, RH, 2001) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "The benefits of digoxin in patients with atrial fibrillation may be reduced due to its limited effect on atrioventricular conduction." | 3.69 | [Comparison between digoxin and atenolol in chronic atrial fibrillation]. ( Castillo, G; Lanas, F; Molina, E; Montecinos, A; Salvatici, R; Stockins, B, 1995) |
| "Treatment with atenolol was associated with a marked reduction in maximum treadmill walking distance (mean 356 m) as compared both with placebo (mean 421 m, p less than 0." | 2.66 | Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. ( Lewis, RV; McDevitt, DG; McMurray, J, 1989) |
| "She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome." | 2.41 | Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium. ( Hattori, K; Hirakawa, Y; Ichihashi, R; Kei, M; Matsubara, K; Saburi, Y; Sakurai, H; Tsukamoto, H; Yokouchi, K, 2000) |
| "Obstructive sleep apnea is associated with sympathovagal disbalance, AF, and postapneic BP rises." | 1.38 | Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. ( Böhm, M; Linz, D; Mahfoud, F; Neuberger, HR; Schotten, U; Ukena, C; Wirth, K, 2012) |
| "Mortality, pulmonary edema, and need for IABP were reduced by >50% (p < 0." | 1.32 | Impact of prophylactic postoperative beta-blockade on post-cardiothoracic surgery length of stay and atrial fibrillation. ( Coleman, CI; Gallagher, R; Gillespie, EL; Horowitz, S; Kluger, J; Perkerson, KA; White, CM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (7.58) | 18.7374 |
| 1990's | 11 (16.67) | 18.2507 |
| 2000's | 38 (57.58) | 29.6817 |
| 2010's | 11 (16.67) | 24.3611 |
| 2020's | 1 (1.52) | 2.80 |
| Authors | Studies |
|---|---|
| Feinberg, JB | 1 |
| Nielsen, EE | 1 |
| Kjeldsen, SE | 11 |
| Devereux, RB | 13 |
| Gerdts, E | 4 |
| Wachtell, K | 13 |
| Olsen, MH | 8 |
| Irie, M | 1 |
| Tsuneoka, Y | 1 |
| Shimobayashi, M | 1 |
| Hasegawa, N | 1 |
| Tanaka, Y | 1 |
| Mochizuki, S | 1 |
| Ichige, S | 1 |
| Hamaguchi, S | 1 |
| Namekata, I | 1 |
| Tanaka, H | 1 |
| Rojas-Perez-Ezquerra, P | 1 |
| Noguerado-Mellado, B | 1 |
| Morales-Cabeza, C | 1 |
| Zambrano Ibarra, G | 1 |
| Datino Romaniega, T | 1 |
| Kiselev, AR | 1 |
| Gridnev, VI | 1 |
| Prokhorov, MD | 1 |
| Karavaev, AS | 1 |
| Posnenkova, OM | 1 |
| Ponomarenko, VI | 1 |
| Bezruchko, BP | 1 |
| Okin, PM | 7 |
| Hille, DA | 4 |
| Boman, K | 2 |
| Dahlöf, B | 13 |
| Larstorp, AC | 2 |
| Van Gelder, IC | 1 |
| Rienstra, M | 1 |
| Crijns, HJ | 1 |
| Olshansky, B | 2 |
| Dabrowski, R | 1 |
| Sosnowski, C | 1 |
| Michalak, E | 1 |
| Szwed, H | 1 |
| Gopinathannair, R | 1 |
| Sullivan, RM | 1 |
| Julius, S | 5 |
| Lindholm, LH | 6 |
| Nieminen, MS | 6 |
| Edelman, JM | 4 |
| Aurigemma, GP | 1 |
| Palmieri, V | 1 |
| Rokkedal, JE | 1 |
| Ariansen, I | 2 |
| Reims, HM | 1 |
| Gjesdal, K | 2 |
| Ibsen, H | 7 |
| Marshall, LL | 1 |
| Linz, D | 1 |
| Mahfoud, F | 1 |
| Schotten, U | 1 |
| Ukena, C | 1 |
| Neuberger, HR | 1 |
| Wirth, K | 1 |
| Böhm, M | 1 |
| Yazicioglu, L | 1 |
| Eryilmaz, S | 1 |
| Sirlak, M | 1 |
| Inan, MB | 1 |
| Aral, A | 1 |
| Tasoz, R | 1 |
| Akalin, H | 1 |
| Good, L | 1 |
| Côté, E | 1 |
| Wright, KN | 1 |
| Doskina, EV | 1 |
| Kanorskiĭ, SG | 1 |
| Zingilevskiĭ, KB | 1 |
| Kamiyama, N | 1 |
| Koyama, Y | 1 |
| Suetsuna, R | 1 |
| Saito, Y | 1 |
| Kaji, S | 1 |
| Akasaka, T | 1 |
| Yoshida, K | 1 |
| Nadar, S | 1 |
| Lim, HS | 1 |
| Lip, GY | 1 |
| Borch-Johnsen, K | 1 |
| Snapinn, S | 1 |
| Diener, HC | 1 |
| Merritt, JC | 1 |
| Niebauer, M | 1 |
| Tarakji, K | 1 |
| Hammer, D | 1 |
| Mills, RM | 1 |
| Stöllberger, C | 1 |
| Slany, J | 1 |
| Brainin, M | 1 |
| Finsterer, J | 1 |
| Sanjuán, R | 1 |
| Blasco, M | 1 |
| Carbonell, N | 1 |
| Jordá, A | 1 |
| Núñez, J | 1 |
| Martínez-León, J | 1 |
| Otero, E | 1 |
| Tamariz, LJ | 1 |
| Bass, EB | 1 |
| Coleman, CI | 1 |
| Perkerson, KA | 1 |
| Gillespie, EL | 1 |
| Kluger, J | 1 |
| Gallagher, R | 1 |
| Horowitz, S | 1 |
| White, CM | 1 |
| Kizer, JR | 1 |
| Beevers, G | 1 |
| de Faire, U | 1 |
| Fyhrquist, F | 2 |
| Kristianson, K | 1 |
| Lederballe-Pedersen, O | 1 |
| Omvik, P | 1 |
| Oparil, S | 1 |
| Wedel, H | 1 |
| Snapinn, SM | 1 |
| Harris, KE | 2 |
| Hornestam, B | 2 |
| Lehto, M | 2 |
| Slotwiner, DJ | 1 |
| Aurup, P | 1 |
| Rokkedal, J | 1 |
| Bourassa, MG | 1 |
| Patterson, E | 1 |
| Po, SS | 1 |
| Scherlag, BJ | 1 |
| Lazzara, R | 1 |
| Nattel, S | 2 |
| Franklin, SS | 1 |
| Papademetriou, V | 1 |
| Ogimoto, A | 1 |
| Shigematsu, Y | 1 |
| Hara, Y | 1 |
| Ohtsuka, T | 1 |
| Miki, T | 1 |
| Higaki, J | 1 |
| Baumgart, P | 2 |
| Komaroff, AL | 1 |
| Jern, S | 1 |
| Menezes, Ada S | 1 |
| Martinelli Filho, M | 1 |
| Menezes, CC | 1 |
| Costa, R | 1 |
| Ramires, JA | 1 |
| Fogari, R | 1 |
| Zoppi, A | 1 |
| Mugellini, A | 1 |
| Corradi, L | 1 |
| Lazzari, P | 1 |
| Preti, P | 1 |
| Derosa, G | 1 |
| Vagaonescu, TD | 1 |
| Wilson, AC | 1 |
| Kostis, JB | 1 |
| Tuncer, M | 1 |
| Fettser, DV | 1 |
| Gunes, Y | 1 |
| Batyraliev, TA | 1 |
| Guntekin, U | 1 |
| Gumrukchuoglu, KhA | 1 |
| Eryonucu, B | 1 |
| Guler, N | 1 |
| Sidorenko, BA | 1 |
| Rasmussen, K | 1 |
| Andersen, K | 1 |
| Wang, H | 1 |
| Channer, KS | 2 |
| James, MA | 1 |
| MacConnell, T | 1 |
| Rees, JR | 1 |
| Carmona, J | 1 |
| Amado, P | 1 |
| Castanheira, J | 1 |
| Nazaré, J | 1 |
| Araújo, V | 1 |
| Lanas, F | 1 |
| Salvatici, R | 1 |
| Castillo, G | 1 |
| Montecinos, A | 1 |
| Stockins, B | 1 |
| Molina, E | 1 |
| Girona, J | 1 |
| Domingo, A | 1 |
| Albert, D | 1 |
| Casaldàliga, J | 1 |
| Mont, L | 1 |
| Brugada, J | 1 |
| Brugada, R | 1 |
| Hnatkova, K | 3 |
| Murgatroyd, FD | 3 |
| Guo, X | 3 |
| Camm, AJ | 3 |
| Malik, M | 3 |
| Waktare, JE | 2 |
| Gallagher, MM | 1 |
| Farshi, R | 1 |
| Kistner, D | 1 |
| Sarma, JS | 1 |
| Longmate, JA | 1 |
| Singh, BN | 1 |
| Steeds, RP | 1 |
| Birchall, AS | 1 |
| Smith, M | 1 |
| de la Sierra, A | 1 |
| Kuznetsov, AS | 1 |
| Sakurai, H | 1 |
| Kei, M | 1 |
| Matsubara, K | 1 |
| Yokouchi, K | 1 |
| Hattori, K | 1 |
| Ichihashi, R | 1 |
| Hirakawa, Y | 1 |
| Tsukamoto, H | 1 |
| Saburi, Y | 1 |
| Gage, BF | 1 |
| Fihn, SD | 1 |
| White, RH | 1 |
| Schley, G | 1 |
| Beckmann, R | 1 |
| Hengstebeck, W | 1 |
| Capucci, A | 2 |
| Verardi, P | 1 |
| Binetti, G | 1 |
| Bracchetti, D | 2 |
| Ambrosioni, E | 1 |
| Magnani, B | 2 |
| De Garaté, S | 1 |
| Di Ciò, G | 1 |
| Carini, G | 1 |
| Lewis, RV | 1 |
| McMurray, J | 1 |
| McDevitt, DG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| The Systemic Effects of Transcatheter Renal Artery Sympathetic Denervation Using a Second- Generation Radiofrequency Ablation Catheter: A Multicenter Observational Study.[NCT05744986] | 100 participants (Anticipated) | Observational [Patient Registry] | 2022-11-22 | Recruiting | |||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG[NCT03227393] | 0 participants (Actual) | Interventional | 2017-09-30 | Withdrawn (stopped due to Study was not opened at site.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for atenolol and Atrial Fibrillation
| Article | Year |
|---|---|
Rate control in atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atenolol; Atrial Fibri | 2016 |
Gastrointestinal bleeding and possible hypothyroidism.
Topics: Aged, 80 and over; Amiodarone; Anemia; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroid | 2012 |
Implications of the LIFE trial.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; At | 2003 |
Pharmacological rate control of atrial fibrillation.
Topics: Amiodarone; Atenolol; Atrial Fibrillation; Cardiotonic Agents; Digoxin; Diltiazem; Heart Rate; Human | 2004 |
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2007 |
Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Atrial Fibrillation; Bradycardia; Calcium Channel Block | 2000 |
Warfarin therapy for an octogenarian who has atrial fibrillation.
Topics: Aged; Aged, 80 and over; Analgesics; Anticoagulants; Antihypertensive Agents; Atenolol; Atrial Fibri | 2001 |
25 trials available for atenolol and Atrial Fibrillation
| Article | Year |
|---|---|
Sex Differences in Atrial Fibrillation and Associated Complications in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study.
Topics: Atenolol; Atrial Fibrillation; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left | 2023 |
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure | 2015 |
Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Double-Blind Method; E | 2015 |
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2008 |
Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
Topics: Aged; Alcohol Drinking; Analysis of Variance; Antihypertensive Agents; Atenolol; Atrial Fibrillation | 2012 |
Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Comorbidity; Double-Bl | 2012 |
The effect of preoperative digitalis and atenolol combination on postoperative atrial fibrillation incidence.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Cor | 2002 |
Preoperative use of sotalol versus atenolol for atrial fibrillation after cardiac surgery.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atenolol; Atrial Fi | 2004 |
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2005 |
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol?
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Atenolol; | 2005 |
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Double-Blind Method; Electrocardiograp | 2006 |
Effects of the association of dual-site dynamic atrial overdrive and atenolol in preventing recurrent atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; C | 2007 |
Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Bl | 2008 |
Atrial fibrillation and isolated systolic hypertension: the systolic hypertension in the elderly program and systolic hypertension in the elderly program-extension study.
Topics: Aged; Aged, 80 and over; Aging; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressu | 2008 |
[Comparison of effects of nebivolol and atenolol on P-wave dispersion in patients with hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Benzopyra | 2008 |
Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Atenolol; Atrial Fibrillation; Bradycardia; | 1994 |
Graphical representation of complex data--diurnal patterns of initiations of atrial fibrillation episodes.
Topics: Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Circadian Rhythm; Computer Graphics; Cross-Ov | 1997 |
Age and gender influences on rate and duration of paroxysmal atrial fibrillation.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Cross-Over Studies; Digoxi | 1998 |
Evolution of changes in the ventricular rhythm during paroxysmal atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Cross-Over Studies; Digoxin; Disopyramide; Do | 1998 |
Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens.
Topics: Aged; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Calcium Channel Blockers; Circadian Rhy | 1999 |
An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Atrial Fibrillation; Cross-Over Studies; Drug Administr | 1999 |
[Relationship between sympathetic activity and response to treatment with atenolol in hypertensive patients. Investigation group of the study of efficiency and tolerance of atenolol in hypertensive patients with increase in the sympathetic activity].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anxiety; Atenolol; Atrial Fibrillation; Female; Heart Ra | 1999 |
Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
Topics: Adrenergic beta-Agonists; Aged; Atenolol; Atrial Fibrillation; Chronic Disease; Digitalis Glycosides | 1989 |
34 other studies available for atenolol and Atrial Fibrillation
| Article | Year |
|---|---|
Involvement of alpha- and beta-adrenoceptors in the automaticity of the isolated guinea pig pulmonary vein myocardium.
Topics: Animals; Atenolol; Atrial Fibrillation; Carbazoles; Carvedilol; Guinea Pigs; In Vitro Techniques; Ma | 2017 |
Atrial Fibrillation in Anaphylaxis.
Topics: Actinidia; Administration, Intravenous; Adult; Aged, 80 and over; Anaphylaxis; Animals; Anisakis; An | 2017 |
Effects of antihypertensive treatment on cardiovascular autonomic control: a prospective study.
Topics: Antihypertensive Agents; Atenolol; Atrial Fibrillation; Autonomic Nervous System; Cohort Studies; En | 2014 |
A beneficial effect of 3-year spironolactone therapy supplementing atenolol therapy on the remodeling of atria and ventricles in a patient with permanent atrial fibrillation.
Topics: Adult; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Heart Atria; Heart Ventricles; Humans; | 2009 |
Slower heart rates for healthy hearts: time to redefine tachycardia?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2008 |
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Blood Pressure; | 2010 |
Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea.
Topics: Adrenergic beta-1 Receptor Antagonists; Anesthesia; Animals; Anti-Arrhythmia Agents; Atenolol; Atria | 2012 |
ECG of the month. Narrow-complex monomorphic tachycardia with a ventricular rate of 320 beats/min.
Topics: Animals; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Diagnosis, Differential; Digoxin; Do | 2002 |
[A case of familial restrictive cardiomyopathy].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Aspirin; Atenolol; Atrial Fibrillation | 2002 |
[Comparative effects of amiodarone, diltiazem, and atenolol on results of electrical cardioversion in patients with chronic atrial fibrillation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Chronic Disease; Dil | 2002 |
Decreased left atrial appendage flow velocity with atrial fibrillation caused by negative inotropic agents: report of two cases.
Topics: Atenolol; Atrial Fibrillation; Atrial Function, Left; Blood Flow Velocity; Cardiotonic Agents; Echoc | 2003 |
[Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; At | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Carbazoles; Carvedilol; Coronary | 2003 |
Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Atrial Fibrillation; Clinical Trials as Topic; F | 2003 |
Impact of prophylactic postoperative beta-blockade on post-cardiothoracic surgery length of stay and atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Atrial Fibrillation; Cardiac Surgical Procedures; Cohor | 2004 |
Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation.
Topics: Animals; Atenolol; Atrial Fibrillation; Atropine; Autonomic Nervous System; Dogs; Electric Stimulati | 2005 |
Combined parasympathetic-sympathetic nerve discharge and pulmonary vein afterdepolarizations: a new unifying concept with basic and clinical relevance.
Topics: Animals; Atenolol; Atrial Fibrillation; Atropine; Autonomic Nervous System; Dogs; Electric Stimulati | 2005 |
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; At | 2005 |
Black pearl in the LIFE study: angiotensin-II receptor blockade on atrial fibrillation for future personalized medicine.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Bla | 2005 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
By the way, doctor. I am 81 with no history of heart problems. I recently developed atrial fibrillation and now take half of a 25-mg tablet of atenolol. The doctor says it's working, but it makes me extremely tired. Could you suggest another medication th
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Fatigue; Humans | 2006 |
[Plus point -- risk reduction].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents | 2006 |
[Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Atrial fibrillation induced by atenolol.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Electrocardiography; Female; Human | 1982 |
[Paroxysmal atrial fibrillation and flutter and "occult" arterial hypertension. The importance of the ambulatory monitoring of the blood pressure. Apropos 2 cases].
Topics: Atenolol; Atrial Fibrillation; Atrial Flutter; Blood Pressure Monitors; Diltiazem; Drug Therapy, Com | 1993 |
[Comparison between digoxin and atenolol in chronic atrial fibrillation].
Topics: Adult; Aged; Analysis of Variance; Atenolol; Atrial Fibrillation; Blood Pressure; Chronic Disease; C | 1995 |
[Familial auricular fibrillation].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Anticoagulants; Atenolol; Atrial Fibrillation; Digo | 1997 |
[The treatment of tachy-systolic fibrillation in a patient after aortocoronary shunting].
Topics: Anti-Arrhythmia Agents; Arteriovenous Shunt, Surgical; Atenolol; Atrial Fibrillation; Humans; Male; | 1999 |
[The treatment of acute cardiac dysrhythmias with atenolol (Tenormin) particularly after myocardial infarction (author's transl)].
Topics: Acute Disease; Adult; Aged; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Atrial Flutter; Car | 1978 |
[Evaluation of the electrophysiological properties of atenolol and of the combination of quinidine and atenolol in humans].
Topics: Adult; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Atrioventricular Node; Drug Evaluation; | 1979 |
[Comparative study with computerized analysis of the effects of amiodarone and atenolol on the R-R intervals in patients with stabilized atrial fibrillation].
Topics: Amiodarone; Atenolol; Atrial Fibrillation; Benzofurans; Electrocardiography; Heart Rate; Humans; Pro | 1978 |